iOrganBio Launches AI-Powered Cell Manufacturing Platform with $2M Funding

iOrganBio emerges from stealth with $2 million funding and launches CellForge, an AI-powered cell manufacturing platform. The platform combines AI-driven prediction with high-throughput experimental control to engineer cells and organoids for drug discovery, manufacturing, and cell therapies. CellForge uses closed-loop control of 3D culture environments to optimize culture conditions during human pluripotent stem cell differentiation, enabling predictable and reproducible outcomes. The platform can be applied in various contexts, including disease modeling, regenerative medicine, and drug development.